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Abstract
Background: Adult granulosa cell tumor associated with antecedent use of tamoxifen as adjuvant
hormonotherapy for breast cancer is rare. The pathogenesis of this occurrence remains difficult to explain. The
estrogenic effect of tamoxifen can be one such explanation.
Case presentation: A 47 year-old women was treated with surgery, chemotherapy, radiotherapy and tamoxifen for
stage III estrogen receptor positive breast carcinoma. Ten months after stopping tamoxifen, we diagnosed a stage
Ic granulosa cell tumor of the ovary.
Conclusions: Use of tamoxifen has been found to be associated with gynecological tumors like endometrial
carcinoma. Its association with granulosa cell tumor of the ovary is uncommon. Only two previous cases have
been reported in literature.
Background
Granulosa cell tumor is a relatively uncommon ovarian
neoplasm accounting for 1% to 2% of all ovarian tumors
[1]. Tamoxifen is a non steroidal triphenylethylene that
competitively antagonizes the binding of estradiol to
estrogen receptor-positive breast carcinoma[2-5]. The
occurrence of granulosa cell tumors in patients with
antecedent tamoxifen has been previously reported in
two patients[6,7]. Although tamoxifen has anti-estrogenic
properties, it is converted to several metabolites that can
act as estrogen agonists [6]. We report the third case of
granulosa cell tumor of the ovary associated with tamoxi-
fen use for breast carcinoma.
Case presentation
A 47-year-old gravidia 3, para 3 women with che-
motherapy induced menopause, had been diagnosed
with stage III(T2 N2M0) infiltrating ductal carcinoma of
the right breast 5 years before the development of a
bilateral granulosa cell tumor of the ovary. After Patey’s
mastectomy, patient has received 6 cycle of anthracy-
cline based chemotherapy (AC 60 protocol: adriamycin
at 60 mg/m
2 and cyclophosphamide at 600 mg/m
2)a n d
a d j u v a n tr a d i o t h e r a p ya tac u m u l a t i v ed o s eo f5 0G y .
The estrogen receptors were strongly positive and the
patient received tamoxifen at a dose of 20 mg as single
d a i l yd o s es i n c eJ a n u a r y2 0 0 4 .T h et a m o x i f e nw a s
stopped after 5 years. In February 2009, one month after
that the patient has stopped the tamoxifen therapy, a
nodule in the left ovary was discovered during a laparo-
scopy for tubal ligation. A left oopherectomy was done,
the pathological results showed a granulosa cell tumor.
Following this a total hysterectomy, right salpingo-
oophorectomy, omentectomy, pelvic and peritoneal
washings and multiple peritoneal biopsies were done.
The histopathological analysis showed a granulosa cell
tumor of the right ovary with capsular rupture in the
left ovary, moderate nuclear atypia and mitotic activity
ranged between 3 and 5 per ten high-power-fields. His-
tological evaluation of uterus showed a proliferative
endometrial lining. The tumor was classified as stage Ic
according to the FIGO classification. The case of our
patient was discussed in the multidisciplinary meeting
and it was decided to keep her on a close follow-up.
Thirteen months after initial diagnosis of granulosa cell
of the ovary, she is free of disease. * Correspondence: abahssainhalima@yahoo.fr
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The granulosa cell tumor is a relatively uncommon
ovarian neoplasm accounting 1% to 2% of all ovarian
tumors [1]. These lesions occur most frequently in
menopausal or postmenopausal women and may be
associated with symptoms of estrogen or progesterone
secretion [1]. The relationship between this hormonal
treatment and the occurrence of such an ovarian tumor
is questionable, as so many patients worldwide receive
tamoxifen therapy and only two previous cases has been
reported in literature till date. It’s probable that the
association of granulosa cell tumor and the use of
tamoxifen for breast cancer is just a random observation
and there is no relationship between them.
As mentioned earlier, the granulosa cell tumors in
conjunction with tamoxifen administration for breast
cancer have been reported in literature. The first case
was reported in 1994 by Gherman et al [6] in a 52-year-
old woman. This patient had liver dysfunction induced
by tamoxifen. The authors sug g e s t e dt h a tt h ei m p a i r e d
hepatic metabolism of the tamoxifen may be responsible
for the ovarian tumor in their patient with elevated liver
transaminase levels. The second case was reported in
2002 by Arnould et al [7]; they described a case of
metastases of a breast carcinoma to an adult granulosa
cell tumor in a 63-year-old woman receiving tamoxifen
therapy with a past history of breast carcinoma. No
explanation was provided for the occurrence and that
was only the second case in the literature despite that
the tamoxifen being used by a large number of patients
around the world with breast cancer. Tamoxifen is an
anti-oestrogenic non-steroidal compound widely used
for adjuvant therapy in breast cancer [8]. Its proven effi-
cacy as a chemotherapeutic agent has led to its prophy-
lactic use in the prevention of breast cancer in healthy
women at high risk of developing breast cancer and it
has also shown efficacy in this regard [9]. Despite these
anticarcinogenic properties, tamoxifen is also a carcino-
gen. Women, who take tamoxifen, whether therapeuti-
cally or prophylactically, are at significantly increased
risk of endometrial cancer [9-11]. Tamoxifen is also a
potent liver carcinogen in male and female rats [12],
and induces uterine tumors when administered to neo-
natal [13] and adult rats [14,15]. These findings suggest
an appropriate surveillance of these patients treated
with tamoxifen in order to proceed to an early diagnosis
of secondary gynecological cancers.
Tamoxifen is subject to extensive hepatic metabolism.
Not surprisingly, several of the metabolites are predomi-
nately estrogenic, rather than antiestrogenic. Differences
in tamoxifen metabolism among mice, rats, and humans
probably contribute to variation among species-agonist
versus partial agonist properties [16].
T h em e t a b o l i t eEi sg e n e r a t e db yt h ec a t a b o l i s mo f
tamoxifen, which has a lower affinity for estrogen recep-
tors than tamoxifen [17-19]. However the cis isomer of
metabolite E (tamoxifen with a hydroxyl group in place
of the dimethylaminoethane side chain) is a potent ago-
nist that displays a high affinity for the estrogen recep-
tor [5,20]. This metabolite has been isolated from dog
bile, a species where tamoxifen is predominantly estro-
genic. Wiebe et al have identified metabolite E and
bisphenol in tamoxifen resistant MCF-7 human breast
tumors implanted in athymic nude mice, as well as in
tumors isolated from patients who have undergone
unsuccessful tamoxifen therapy [21,22]. Tamoxifen is
known to exhibit estrogenic effects in other animal spe-
cies. Tucker et al were showed in the studies of tamoxi-
fen oncogenicity an elevated of the incidence of
granulosa cell tumors at 36% in two groups of female
mice receiving 5 or 50 mg/kg of tamoxifen [23]. In their
study on cultured rat granulosa cells, welsh et al proved
that tamoxifen exerts an augmentative, dose-dependent
estrogenic effect on FSH-stimulated aromatase activity
and estrogen production. They demonstrated that
tamoxifen compete with [3H] estradiol for binding to
the ovarian estrogen receptors [24].
Raloxifene and tamoxifen are Selective estrogen recep-
tor modulators (SERMs) that have estrogen agonist
activities on bone and serum lipid metabolism, and
estrogen antagonist activities in mammary tissue in
ovariectomized rats [25-27]. Treatment with raloxifene
for 6 months resulted in disruption of the hypothala-
mic-pituitary-ovarian axis, manifested by increased
plasma concentrations of luteinizing hormone (LH) and
estradiol-17b (E2), and failure of ovulation. Many (56%
to 80%) rats in all raloxifene treated groups had focal,
minimal to slight hyperplasia of granulosa cells within
individual retained follicles. A few treated rats in the
mid- and high-dose groups had more extensive focal
proliferation of granulosa cells. The results of this study
indicate that raloxifene administration to rats causes
increases in granulosa cell hyperplasia [25].
Conclusions
Association between granulosa cell of the ovary and
antecedent use of tamoxifen is very rare. When com-
pared to world wide tamoxifen use among women, it
appears to be just a random appearance and tamoxifen
use does not appear to increase the risk of granulosa
cell tumor of the ovary.
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